Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
CRNX Stock Chart & Stats
$51.32
-$0.61(-1.22%)
At close: 4:00 PM EST
$51.32
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$24.10 - $57.99
Previous CloseN/A
Volume214.21K
Average Volume (3M)1.29M
Market Cap
$5.43B
Enterprise Value$5.20B
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$49.14M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Feb 26, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding102,511,840
10 Day Avg. Volume859,206
30 Day Avg. Volume1,291,882
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)3975.39
P/FCF Ratio-17.97
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.39K
Enterprise Value/Gross Profit3.39K
Enterprise Value/Ebitda-10.96
Forecast
1Y Price Target
$88.64Price Target Upside72.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPhase 2 results reduced uncertainty around the Phase 3 program by demonstrating strong biomarker reductions and informing a trial design that allows steroid tapering and post-dose measurements, increasing the probability of a successful pivotal outcome.
Commercial Launch And Market AccessPalsonify's initial launch showed multiple prescribers, formulary inclusions, and favorable prior authorization outcomes, signaling early commercial traction and improving prospects for revenue growth.
Safety ProfileExtension study observations reported no liver test related adverse events or drug-related serious discontinuations in higher-dose cohorts, supporting a favorable tolerability profile that could ease regulator and clinician acceptance.
Bears Say
Liquidity And Financing RiskHigh annual cash burn and a limited cash runway create financing risk that could force dilutive capital raises if revenue growth does not accelerate as expected.
Regulatory Timeline RiskAn investigational new drug filing delay in Graves' disease introduces regulatory timeline risk and could postpone the anticipated value inflection from that program.
Research Objectivity And CredibilityDisclosure of potential conflicts of interest by a research firm may undermine confidence in published analyses and reduce investor trust in company coverage.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $24.10 and its highest was $57.99 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $5.43B.
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Feb 26, 2026 which is in 27 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$1.244 by -$0.136.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -1.35.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 102,511,840 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$1.38 in its last earnings report, missing expectations of -$1.244. Following the earnings report the stock price went down -8.025%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.64 (72.72% Upside)
$88.64 (72.72% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.27%
12-Months-Change
Fundamentals
Return on Equity
-44.42%
Trailing 12-Months
Asset Growth
27.59%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a successful launch and positive market reception of PALSONIFY, which is expected to drive substantial growth. However, delays in the Graves' disease candidate and the SST3 agonist program were noted. Overall, the sentiment is positive given the successful launch and financial stability.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$88.64
▲(72.72% Upside)
Technical Analysis
Ligand Pharma
―
Ultragenyx Pharmaceutical
―
Apellis Pharmaceuticals
―
―
Kymera Therapeutics
―
Ownership Overview
1.85% Insiders
37.85% Mutual Funds
0.01% Other Institutional Investors
46.17% Public Companies and Individual Investors